ctDNA	circulating tumor DNA
cfDNA	cell-free DNA
MRD	minimal residual disease
GU	genitourinary
NMIBC	non-muscle-invasive bladder cancer
MIBC	muscle-invasive bladder cancer
TURBT	transurethral resection of bladder tumor
NAC	neoadjuvant chemotherapy
RC	radical cystectomy
TMT	trimodality therapy
pCR	pathologic complete response
cCR	clinical complete response
DFS	disease-free survival
RFS	recurrence-free survival
MFS	metastasis-free survival
OS	overall survival
HR	hazard ratio
CI	confidence interval
PPV	positive predictive value
NPV	negative predictive value
BEP	biomarker-evaluable population
DDR	DNA damage repair
RCC	renal cell carcinoma
SABR	stereotactic ablative radiotherapy
M1 NED	metastatic disease with no evidence of disease
BCR	biochemical recurrence
PSA	prostate-specific antigen
PFS	progression-free survival
CTC	circulating tumor cell
utDNA	urinary tumor DNA